• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Rezolute Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/13/25 4:12:34 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RZLT alert in real time by email
    false 0001509261 0001509261 2025-05-13 2025-05-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of report (Date of earliest event reported): May 13, 2025

     

     

    REZOLUTE, INC.

    (Exact Name of Registrant as Specified in Charter)

     

     

    Nevada   001-39683   27-3440894

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

     

    275 Shoreline Drive, Suite 500, Redwood City, CA 94065

    (Address of Principal Executive Offices, and Zip Code)

     

    650-206-4507

    Registrant’s Telephone Number, Including Area Code

     

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report) 

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ¨ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class Trading Symbol(s) Name of each exchange on which registered
    Common Stock, par value $0.001 per share RZLT Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    Item 2.02 Results of Operations and Financial Condition.

     

    On May 13, 2025, Rezolute, Inc. issued a press release announcing its financial results for the third quarter ended March 31, 2025. A copy of this press release is attached hereto as Exhibit 99.1.

     

    The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.

     

    Item 9.01Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No.    Description
    99.1   Press Release, dated May 13, 2025
    104   Cover Page Interactive Data File (formatted as inline XBRL)

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      REZOLUTE, INC.
         
    DATE:  May 13, 2025 By: /s/ Nevan Charles Elam
        Nevan Charles Elam
        Chief Executive Officer 

     

     

    Get the next $RZLT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RZLT

    DatePrice TargetRatingAnalyst
    11/5/2024$12.00Outperform
    Wedbush
    8/27/2024$11.00Buy
    Guggenheim
    7/17/2024$13.00Buy
    BTIG Research
    6/4/2024$14.00Buy
    Craig Hallum
    4/9/2024$8.00Buy
    Maxim Group
    8/2/2022$17.00Buy
    Canaccord Genuity
    6/15/2022$9.00Overweight
    Cantor Fitzgerald
    11/29/2021$30.00 → $17.00Buy
    Canaccord Genuity
    More analyst ratings

    $RZLT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Kreher Nerissa was granted 9,000 shares, increasing direct ownership by 35% to 34,500 units (SEC Form 4)

      4 - Rezolute, Inc. (0001509261) (Issuer)

      6/13/25 6:52:09 PM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Labrucherie Gil M was granted 9,000 shares, increasing direct ownership by 35% to 34,500 units (SEC Form 4)

      4 - Rezolute, Inc. (0001509261) (Issuer)

      6/13/25 2:15:55 PM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Hogenhuis Wladimir was granted 9,000 shares, increasing direct ownership by 11% to 93,025 units (SEC Form 4)

      4 - Rezolute, Inc. (0001509261) (Issuer)

      6/13/25 9:58:47 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RZLT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism

      Target enrollment exceeded with 62 participants enrolled, including approximately 15 percent from U.S. sites Topline data is anticipated in December of 2025 REDWOOD CITY, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI), today announced that enrollment is complete in the sunRIZE study, a global, Phase 3 multicenter, double-blind, randomized, placebo-controlled, parallel arm study designed to evaluate the efficacy and safety of ersodetug for the treatment of hypoglycemia in patients with congenital HI. "The completion of enrollment in the s

      5/28/25 8:00:00 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

      sunRIZE enrollment on track including U.S. sites and expected to be completed in May 2025; topline data anticipated in December 2025 U.S. Food and Drug Administration (FDA) grants Breakthrough Therapy Designation to ersodetug for hypoglycemia due to tumor hyperinsulinism REDWOOD CITY, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI), today reported financial results and provided a business update for the three months ended March 31, 2025. "The Phase 3 sunRIZE study in congenital HI is on track to complete enrollment this month and we are p

      5/13/25 4:05:00 PM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

      Registrational study in patients with tumor hyperinsulinism (HI) expected to commence mid-year Designation underscores need for therapies to treat severe hypoglycemia in the oncology setting REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by HI, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its investigational therapy, ersodetug, for the treatment of hypoglycemia caused by tumor HI.  BTD for ersodetug was granted based on clinical trial data across the overall program and a re

      5/5/25 8:00:00 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RZLT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wedbush initiated coverage on Rezolute with a new price target

      Wedbush initiated coverage of Rezolute with a rating of Outperform and set a new price target of $12.00

      11/5/24 6:25:51 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Rezolute with a new price target

      Guggenheim initiated coverage of Rezolute with a rating of Buy and set a new price target of $11.00

      8/27/24 7:36:43 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research initiated coverage on Rezolute with a new price target

      BTIG Research initiated coverage of Rezolute with a rating of Buy and set a new price target of $13.00

      7/17/24 7:55:53 AM ET
      $RZLT
      Biotechnology: Pharmaceutical Preparations
      Health Care